Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215325 · ClinicalTrials.gov registry record · Phase 4
Got Doxy- 'Flipping the Script' on STI PEP
A Phase 4 study of Sexually Transmitted Infections (STI), sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT07215325: Recruiting Phase 4 study of Sexually Transmitted Infections (STI), sponsored by Emory University.
NCT07215325 is a Phase 4 study of Sexually Transmitted Infections (STI) that is actively recruiting participants, run by Emory University. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215325, a Phase 4 study of Sexually Transmitted Infections (STI), is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to test the effects of doxycycline on inflammation and the bacteria in the body in people with HIV and in people on HIV pre-exposure prophylaxis. This drug is approved by the Food and Drug Administration (FDA) for the treatment of bacterial infections. The study team will investigate whether the drug has additional effects on inflammation or on the bacteria that live in the body.
Primary Outcome
A composite inflammation score in the blood and rectal secretions before and after doxy-PEP will be calculated for each participant: +1 point for each proinflammatory cytokine (IP-10, IL-1β, tumor necrosis factor (TNF-α), Monocyte chemoattractant protein-1 (MCP-1), IL-17A, IL-6, interferon (IFN-γ), IL-12p70, IL-8) that was in the top quartile concentration and -1 point for each anti-inflammatory cytokine (IL-4, IL-10), T-cell growth factor (TGF-β1) that was in the top quartile concentration for
Conditions Studied
Interventions
- OTHER Observation
- DRUG Doxycycline monohydrate 200 mg
Study Locations (2)
Georgia
- Grady Health System (non-CRN) - Atlanta
- Hope Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
What NCT07215325 shows while recruiting
NCT07215325 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Sexually Transmitted Infections (STI) appearing as the primary indexed condition, and to 2 interventions - of which Observation is the first listed.
NCT07215325 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT07215325 about?
NCT07215325 is a clinical study titled "Got Doxy- 'Flipping the Script' on STI PEP". This study is being done to test the effects of doxycycline on inflammation and the bacteria in the body in people with HIV and in people on HIV pre-exposure prophylaxis. This drug is approved by the Food and Drug Administration (FDA) for the treatment of bacterial infections. The study team will i...
What is the current status of trial NCT07215325?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2025-10-22. Estimated completion is 2028-09.
What conditions does trial NCT07215325 study?
This clinical trial studies the following conditions: Sexually Transmitted Infections (STI).
What interventions are being tested in trial NCT07215325?
The interventions under investigation include: Observation (OTHER), Doxycycline monohydrate 200 mg (DRUG).
Who is sponsoring clinical trial NCT07215325?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215325 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexually Transmitted Infections (STI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07215325's enrollment target sits among peer trials
200 407th of 2000 higher than 1,557 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI